ArQule, Inc. (NASDAQ:ARQL) saw some unusual options trading on Wednesday. Investors bought 3,365 put options on the company. This represents an increase of 881% compared to the typical volume of 343 put options.
Shares of NASDAQ ARQL traded up $0.18 during midday trading on Friday, hitting $11.01. 3,590,500 shares of the company’s stock were exchanged, compared to its average volume of 2,204,883. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.45 and a current ratio of 6.45. ArQule has a twelve month low of $2.23 and a twelve month high of $11.11. The company has a market cap of $1.19 billion, a P/E ratio of -68.81 and a beta of 1.96. The firm has a fifty day simple moving average of $7.75.
ArQule (NASDAQ:ARQL) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $1.35 million for the quarter, compared to analyst estimates of $1.70 million. ArQule had a negative return on equity of 28.90% and a negative net margin of 83.15%. On average, analysts anticipate that ArQule will post -0.37 EPS for the current fiscal year.
ARQL has been the subject of a number of research analyst reports. Roth Capital set a $8.00 target price on ArQule and gave the company a “buy” rating in a report on Thursday, March 7th. Oppenheimer set a $8.00 price target on ArQule and gave the company a “buy” rating in a research report on Thursday, March 7th. Zacks Investment Research raised ArQule from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a research report on Monday, March 11th. B. Riley set a $7.00 price target on ArQule and gave the company a “buy” rating in a research report on Friday, March 8th. Finally, ValuEngine lowered ArQule from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 15th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $10.79.
ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer.
See Also: 52-Week High/Low
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.